Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: The third study of the french society of paediatric oncology (EW88 study)

British Journal of Cancer

Volumn 85, Issue 11, 2001, Pages 1646-1654

  Oberlin, O ^a   Deley, M C Le ^a   Bui, B N'Guyen ^b   Gentet, J C ^c   Philip, T ^d   Terrier, P ^a   Carrie, C ^d   Mechinaud, F ^e   Schmitt, C ^f   Babin Boillettot, A ^g   Michon, J ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Oncologie Fondation Bergonié   (France)

^c TIMONE HOSPITAL   (France)

^d CENTRE LÉON BÉRARD   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f HÔPITAL D ENFANTS   (France)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h INSTITUT CURIE   (France)

Author keywords

Chemotherapy; Ewing's tumour; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; MESNA; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BELGIUM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; DRUG RESPONSE; EWING SARCOMA; FEMALE; FOLLOW UP; FRANCE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; PROGNOSIS; RADIOTHERAPY; SARCOMA, EWING'S; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0035977183     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2150     Document Type: Article

References (28)

1. Ewing's sarcoma: Local tumor control and patterns of failure following limited-volume radiation therapy
2. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli
3. Localized Ewing's sarcoma of bone: Ten years' experience at the Istituto Ortopedico Rizzoli in 124 cases treated with multimodal therapy
4. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years
5. Combined therapy of localized Ewing's sarcoma of bone: Analysis of results in 100 patients
6. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1)
7. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: End results of POG #8346
8. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience
9. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents
10. The response of Ewing's sarcoma to sequential cyclophosphamide and adriamycin induction therapy
11. Therapy for localized Ewing's sarcoma of bone
12. Factors associated with tumor volume and primary metastases in Ewing tumors: Results from the (EI)CESS studies
13. Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement
14. The German Society of Pediatric Oncology Cooperative Ewing Sarcoma Studies C ESS 81/86: Report after 6 1/2 years
15. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial
16. Neural differenciation in small cell sarcomas of bone in children and adolescents: Implications for treatment?
17. Non-parametric estimation from incomplete observation
18. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy
19. The prognostic significance of soft tissue extension in Ewing's sarcoma
20. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study
21. The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma
22. No benefit of ifosfamide in Ewing's sarcoma: A nonrandomized study of the French Society of Pediatric Oncology
23. Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior
24. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
25. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities
26. Prognostic factors in the treatment of Ewing's sarcoma
27. Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis?
28. Ewing's sarcoma of bone. Experience with 140 patients